WO2004091511A2 - Compositions et methodes de diagnostic et de traitement du cancer du poumon - Google Patents

Compositions et methodes de diagnostic et de traitement du cancer du poumon Download PDF

Info

Publication number
WO2004091511A2
WO2004091511A2 PCT/US2004/011193 US2004011193W WO2004091511A2 WO 2004091511 A2 WO2004091511 A2 WO 2004091511A2 US 2004011193 W US2004011193 W US 2004011193W WO 2004091511 A2 WO2004091511 A2 WO 2004091511A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
gene
cells
neoplastic
lung
Prior art date
Application number
PCT/US2004/011193
Other languages
English (en)
Other versions
WO2004091511A3 (fr
Inventor
Bruce L. Roberts
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of WO2004091511A2 publication Critical patent/WO2004091511A2/fr
Publication of WO2004091511A3 publication Critical patent/WO2004091511A3/fr
Priority to US11/247,437 priority Critical patent/US20060110753A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • TECHNICAL FIELD This invention is in the field of cancer biology.
  • the present invention provides compositions and methods for identifying a neoplastic lung cell. It also provides compositions and methods to inhibit the growth of neoplastic lung cells identified by these methods.
  • Lung cancer is one of the most common malignancies worldwide and is the second leading cause of cancer death in man. See, American Cancer Society, Cancer
  • NSCLC non-small cell lung cancer
  • small cell lung cancer is the most malignant and fastest growing form of lung cancer and accounts for the rest of approximately 20% of new cases of lung cancer.
  • the primary tumor is generally responsive to chemotherapy, but is followed by wide-spread metastasis.
  • the median survival time at diagnosis is approximately 1 year, with a 5 year survival rate of 5%.
  • successful intervention for lung cancer in particular relies on early detection of the cancerous cells.
  • Neoplasia resulting in benign tumors may be completely cured by removing the mass surgically. If a tumor becomes malignant, as manifested by invasion of surrounding tissue, it becomes much more difficult to eradicate.
  • the present invention provides methods for aiding in the diagnoses of the condition of a lung cell, for identifying and/or distinguishing normal and neoplastic lung cells and for identifying potential therapeutic agents to reverse neoplasia and/or ameliorate the symptoms associated with the presence of neoplastic lung cells in a subject. Further provided are compositions and methods to reverse neoplasia and/or ameliorate the symptoms associated with neoplastic lung cells in vivo.
  • one embodiment is a method of diagnosing the condition of a lung cell by screening for the presence of a differentially expressed gene isolated from a sample containing or suspected of containing a lung cell, in which the differential expression of the gene is indicative of the neoplastic state of the lung cell.
  • the gene is expressed more in a neoplastic lung cell or a lung tumor cell as compared to normal lung cell, and is selected from EGFR-RS, RYK, TNFRSF25, TRPM7, KCP3 and KIAA 1883.
  • the gene is expressed more in a normal lung cell as compared to a neoplastic lung cell, e.g., UNC5H2.
  • the gene was not heretofor known to be associated with lung cancer cells and therefore provides a diagnostic and prognostic marker as well as a therapeutic target.
  • Detection can be by any appropriate method, including for example, detecting the quantity of mRNA transcribed from the gene, or the quantity of cDNA produced from the reverse transcription of the mRNA transcribed from the gene, or the quantity of the polypeptide or protein encoded by the gene. These methods can be performed on a sample by sample basis or modified for high throughput analysis. Additionally, databases containing quantitative full or partial transcripts or protein sequences isolated from a cell sample can be searched and analyzed for the presence and amount of transcript or expressed gene product. The methods are particularly useful for aiding in the diagnosis of non-small cell lung cancer cell.
  • Another aspect of the invention is a screen to identify therapeutic agents that reverse or treat lung neoplasia and tumors, wherem the lung cell and/or tumor is characterized by the differential expression of at least one gene selected from EGFR- RS, RYK, TNFRSF25, TRPM7, KCP3, KIAA 1883 or UNC5H2. (See Table 1).
  • the method comprises contacting the cell previously identified as possessing this genotype with an effective amount of a potential agent and assaying for reversal of the neoplastic condition.
  • kits for use in a diagnostic method or drug screen comprises at least one agent (e.g. , probe, primer or antibody) that detects expression of at least one gene identified in Table 1 and instructions for use.
  • agent e.g. , probe, primer or antibody
  • polynucleotides encoding tl e proteins, fragments thereof, or polypeptides (also referred to herein as a gene expression product), gene delivery vehicles comprising these polynucleotides and host cells comprising these polynucleotides.
  • the proteins, polypeptides or fragments thereof are also useful to generate antibodies that specifically recognize and bind to these molecules.
  • the antibodies can be polyclonal or monoclonal. These antibodies can be used to isolate protein or polypeptides expressed from the genes identified in Table 1. These antibodies are further useful for passive immunotherapy when administered to a subject.
  • the invention also provides isolated host cells and recombinant host cells that contain a gene of Table 1 or its expression product and/or fragments of either.
  • the cells can be prokaryotic or eukaryotic and by way of example only, can be any one or more of bacterial, yeast, animal, mammalian, human, and particular subtypes thereof, e.g., stem cells, antigen presenting cells (APCs) such as dendritic cells (DCs) or T cells.
  • APCs antigen presenting cells
  • DCs dendritic cells
  • the invention provides methods for active immunotherapy, such as, inducing an immune response in a subject by delivering the proteins, polypeptides and fragments of either, as described herein, to the subject.
  • the proteins and/or polypeptides can be delivered in the context of an MHC molecule.
  • the invention also provides immune effector cells raised in vivo or in vitro in the presence and at the expense of an antigen presenting cell that presents a polypeptide fragment expressed from a gene identified in Table 1, supra, in the context of an MHC molecule.
  • the invention also provides a method of adoptive immunotherapy comprising administering an effective amount of these immune effector cells to a subject.
  • Yet another embodiment of the present invention is a method of reversing the neoplastic condition of a lung cell, wherein the cell is characterized by differential expression of a gene identified in Table 1, by contacting the cell with a therapeutic agent.
  • SEQ ID NO: 1 is a polynucleotide sequence encoding an EGFR-RS polypeptide.
  • SEQ ID NO: 2 is a polypeptide sequence encoded from an EGFR-RS gene.
  • SEQ ID NO: 3 is a polynucleotide sequence encoding a RYK polypeptide.
  • SEQ ID NO:4 is a polypeptide sequence encoded from an RYK gene.
  • SEQ ID NO:5 is a polynucleotide sequence encoding a TNFRSF25 polypeptide.
  • SEQ ID NO:6 is a polypeptide sequence encoded from a TNFRSF25 gene.
  • SEQ ID NO:7 is a polynucleotide sequence encoding a TRPM7 polypeptide.
  • SEQ ID NO: 8 is a polypeptide sequence encoded from a TRPM7 gene.
  • SEQ ID NO:9 is a polynucleotide sequence encoding a UNC5H2 polypeptide.
  • SEQ ID NO: 10 is a polypeptide sequence encoded from a UNC5H2 gene.
  • SEQ ID NO: 11 is a polynucleotide sequence encoding a KCP3 polypeptide.
  • SEQ ID NO: 12 is a polypeptide sequence encoded from a KCP3 gene.
  • SEQ ID NO:13 is a polynucleotide sequence encoding a KIAA1883 polypeptide.
  • SEQ ID NO: 14 is a polypeptide sequence encoded from a KIAA1883 gene.
  • BIOLOGY F. M. Ausubel, et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R.I. Freshney, ed. (1987)).
  • polynucleotide and “oligonucleotide” are used interchangeably, and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment (for example, a probe, primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer
  • RNA ribosomal RNA
  • ribozymes cDNA
  • recombinant polynucleotides branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • a polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer.
  • the sequence of nucleotides can be interrupted by non-nucleotide components.
  • a polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component.
  • any embodiment of this invention that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.
  • a polynucleotide is composed of a specific sequence of four nucleotide bases: ademne (A); cytosine (C); guanme (G); thymme (T); and uracil (U) for guanine when the polynucleotide is RNA.
  • A ademne
  • C cytosine
  • G guanme
  • T thymme
  • U uracil
  • polynucleotide sequence is the alphabetical representation of a polynucleotide molecule. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching.
  • a “gene” refers to a polynucleotide containing at least one open reading frame (ORF) that is capable of encoding a particular polypeptide or protein after being transcribed and translated. Any of the polynucleotides sequences described herein may be used to identify larger fragments or full-length coding sequences of the gene with which they are associated. Methods of isolating larger fragment sequences are known to those of skill in the art.
  • a “gene product” or alternatively a “gene expression product” refers to the amino acid (e.g., peptide or polypeptide) generated when a gene is transcribed and translated.
  • polypeptide is used interchangeably with the term “protein” and in its broadest sense refers to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics.
  • the subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc.
  • amino acid refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
  • a peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein.
  • Under transcriptional control is a term well understood in the art and indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operatively linked to an element which contributes to the initiation of, or promotes, transcription. "Operatively linked” refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.
  • EGFR-RS gene refers to at least the ORF of a contiguous polynucleotide sequence and that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • SEQ ID NO: 1 is one example of an
  • EGFR-RS gene and others are known in the art, examples of which include, but are not limited to the sequences set forth under GenBank Accession Nos: NM_022450.2 and the sequences that encode EGFR-RS gene expression products as defined herein. Also included within this definition are biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO:2 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 1, and as determined by percent identity sequence analysis run under default parameters. Also within this definition are biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand.
  • non-human genes the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.57988. Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AA653398.1; AI671048.1; AA858091.1 and AI128203.1. These are particularly useful as probes or primers.
  • EGFR-RS gene expression product, protein or polypeptide includes the amino acid sequence of SEQ ID NO: 2 as well as the amino acid sequences transcribed and translated from the EGFR-RS genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO:2 and which have the biological activity as shown in Table 1.
  • homologous amino acid sequences include, but are not limited to polypeptides having the amino acid sequence of SEQ ID NO: 2 or another EGFR-RS gene expression product that has been modified by conservative amino acid substitutions.
  • RYK gene refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • Sequence ID NO: 3 is one example of an RYK gene, and others are known in the art, examples of which include, but are not limited to the sequences set forth under NCBI RefSeq NM 002958.1 and GenBank Accession Nos.: NB 00_2958.1, X96588.1, BC0217001, S59184.1; X69970.1;
  • X96588.1 and the sequences that encode RYK gene expression products as defined herein.
  • biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO:4 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 3, and as determined by percent identity sequence analysis run under default parameters.
  • biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non-human genes, the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.79350. Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AA845370.1; AI698284.1; and AI500529.1. These are particularly useful as probes or primers.
  • RYK gene expression product, protein or polypeptide includes the amino acid sequence of SEQ ID NO: 4 as well as the amino acid sequences transcribed and translated from the RYK genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO: 4 and which have the biological activity as shown in Table 1. Examples of homologous amino acid sequences include, but are not limited to polypeptides have the amino acid sequence of SEQ ID NO: 4 or other RYK gene expression product that has been modified by conservative amino acid substitutions.
  • TNFRSF25 or "DR3" gene” refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1. Chinnaiyan A.M. et al. (1996)
  • Sequence ID NO: 5 is one example of a DR3 gene, and others are known in the art, examples of which include, but are not limited to the sequences set forth under GenBank Accession Nos.: NM_003790.2; NM_148974.1; NM_148973.1; NM_148972.1, NM_148971.1, and the sequences that encode TNFRSF25 gene expression products as defined herein. Also included within this definition are biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO: 6 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 5, and as determined by percent identity sequence analysis run under default parameters.
  • genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non-human genes, the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.180338. Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AI203624.1; AI424936.1; AI140043.1; and
  • TNFRSF25 Gene expression product, protein or polypeptide includes the amino acid sequence of SEQ ID NO: 6 as well as the amino acid sequences transcribed and translated from the TNFRSF25 genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO: 6 and which have the biological activity as shown in Table 1.
  • TRPM7 gene refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • Sequence ID NO: 7 is one example of a TRPM7 gene, and others are known in the art examples of which include, but are not limited to the sequences set forth under GenBank Accession No. NMO 17672.1 and the sequences that encode TRPM7 gene expression products as defined herein.
  • biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO: 8 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 7 and as determined by percent identity sequence analysis run under default parameters.
  • biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non- human genes, the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.267914.
  • Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AI687022.1; AI926826.1; AI761540.1; and AI814269.1. These are particularly useful as probes or primers.
  • TRPM7 gene expression product, protein or polypeptide includes the amino acid sequence of SEQ ID NO: 8 as well as the amino acid sequences transcribed and translated from the TRPM7 genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95%o homologous to SEQ ID NO: 8 and which have the biological activity as shown in Table 1. Examples of homologous amino acid sequences include, but are not limited to polypeptides having the amino acid sequence of SEQ ID NO: 8 or another TRPM7 gene expression product that has been modified by conservative amino acid substitutions.
  • UNC5H2 gene refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • Sequence ID NO: 9 is one example of an UNC5H2 gene, and others are known in the art, examples of which include, but are not limited to the sequences set forth under GenBank Accession No. NM_170744.1 and the sequences that encode UNC5H2 gene expression products as defined herein.
  • biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO: 10 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 9 and as determined by percent identity sequence analysis run under default parameters.
  • biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non-human genes, the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.183918.
  • polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AK022859.1; AK094595.1 ; and AY126437.1. These are particularly useful as probes or primers.
  • the term "UNC5H2" gene expression product, protein or polypeptide” includes the amino acid sequence of SEQ ID NO: 10 as well as the amino acid sequences transcribed and translated from the UNC5H2 genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO: 10 and which have the biological activity as shown in Table 1.
  • homologous amino acid sequences include, but are not limited to polypeptides having the amino acid sequence of SEQ ID NO: 10 or another UNC5H2 gene expression product that has been modified by conservative amino acid substitutions.
  • KCP3 gene refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • SEQ ID NO: 11 is one example of an KCP3 gene, and others are known in the art examples of which include, but are not limited to the sequences set forth under GenBank Accession No. NM_173853 and the sequences that encode KCP3 gene expression products as defined herein.
  • biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO: 12 and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 11 and as determined by percent identity sequence analysis run under default parameters.
  • biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non- human genes, the polynucleotide sequences of which are known in the art. Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos. : AA531276.1 ; AI831051.1 ; and W93943.1. These are particularly useful as probes or primers.
  • KCP3 gene expression product, protein or polypeptide includes the amino acid sequence of SEQ ID NO: 12 as well as the amino acid sequences transcribed and translated from the KCP3 genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO: 12 and which have the biological activity as shown in Table 1.
  • homologous amino acid sequences include, but are not limited to polypeptides having the amino acid sequence of SEQ ID NO: 12 or another KCP3 gene expression product that has been modified by conservative amino acid substitutions.
  • KIAA1883 gene refers to at least the ORF of a contiguous polynucleotide sequence that encodes a protein or polypeptide having the biological activity as set forth in Table 1.
  • Sequence ID NO: 13 is one example of an KIAA1883 gene, and others are known in the art, examples of which include, but are not limited to the sequences set forth under GeriBank Accession No. XM_055866 and AB067470, and the sequences that encode TRPM7 gene expression products as defined herein.
  • biologically equivalent sequences such as those sequences that code for the polypeptide of SEQ ID NO: 14 (or alternatively, the sequence identified under GenBank Accession Nos.: BAB67776) and those having at least 90% or alternatively, at least 95% sequence homology to an exemplary sequence, such as SEQ ID NO: 13 and as determined by percent identity sequence analysis run under default parameters.
  • biologically equivalent genes or polynucleotides that are identified by the ability to hybridize under conditions of high stringency to the minus strand. It may be desirable to use non-human genes, the polynucleotide sequences of which are known in the art. See for example, UniGene Cluster Hs.281328.
  • Polynucleotide fragments are also known in the art, and include but are not limited to GenBank Accession Nos.: AW044638.1; H51141.1; AW015335.1; and BE466321.1. These are particularly useful as probes or primers.
  • the term "KIA1883 gene expression product, protein or polypeptide” includes the amino acid sequence of SEQ ID NO: 14 as well as the amino acid sequences transcribed and translated from the KIA1883 genes identified above, without regard to the gene expression system, e.g., bacterial or other prokaryotic cell, yeast cell, or mammalian cell such as a simian, bovine or human cell.
  • the term includes isolated, naturally occurring polypeptides isolated from tissue samples as well as recombinantly produced proteins and polypeptides.
  • the term also includes polypeptides having the amino acid sequences that are at least 90% or alternatively at least 95% homologous to SEQ ID NO: 14 and which have the biological activity as shown in Table 1. Examples of homologous amino acid sequences include, but are not limited to polypeptides having the amino acid sequence of SEQ ID NO: 14 or another KIA1883 gene expression product that has been modified by conservative amino acid substitutions.
  • compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination.
  • compositions consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
  • isolated means separated from constituents, cellular and otherwise, in which the polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, are ' normally associated with in nature.
  • an isolated polynucleotide is separated from the 3' and 5' contiguous nucleotides with which it is normally associated with in its native or natural environment, e.g., on the chromosome.
  • a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof does not require "isolation" to distinguish it from its naturally occurring counterpart.
  • a "concentrated”, “separated” or “diluted” polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is greater than “concentrated” or less than “separated” than that of its naturally occurring counterpart.
  • a non-naturally occurring polynucleotide is provided as a separate embodiment from the isolated naturally occurring polynucleotide.
  • a protein produced in a bacterial cell is provided as a separate embodiment from the naturally occurring protein isolated from a eukaryotic cell in which it is produced in nature.
  • Gene delivery are terms referring to the introduction of an exogenous polynucleotide (sometimes referred to as a "transgene") into a host cell, irrespective of the method used for the introduction.
  • transgene exogenous polynucleotide
  • Such methods include a variety of well-known techniques such as vector-mediated gene transfer (by, e.g., viral infection/transfection, or various other protein-based or lipid-based gene delivery complexes) as well as techniques facilitating the delivery of
  • the introduced polynucleotide may be stably or transiently maintained in the host cell. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome.
  • a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome.
  • a number of vectors are known in the art to be capable of mediating transfer of genes to mammalian cells.
  • a “gene delivery vehicle” is defined as any molecule that can carry inserted polynucleotides into a host cell.
  • Examples of gene delivery vehicles are liposomes, biocompatible polymers, including natural polymers and synthetic polymers; lipoproteins; polypeptides; polysaccharides; lipopolysaccharides; artificial viral envelopes; recombinant yeast cells, metal particles; and bacteria, or viruses, such as baculovirus, adenovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
  • a "viral vector” is defined as a recombinantly produced virus or viral particle that comprises a polynucleotide to be delivered into a host cell, either in vivo, ex vivo or in vitro.
  • viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors, alphavirus vectors and the like.
  • Alphavirus vectors such as Semliki Forest virus-based vectors and Sindbis virus-based vectors, have also been developed for use in gene therapy and immunotherapy. See, Schlesinger and
  • a vector construct refers to the polynucleotide comprising the retroviral genome or part thereof, and a therapeutic gene.
  • retroviral mediated gene transfer or “retroviral transduction” carries the same meaning and refers to the process by which a gene or nucleic acid sequences are stably transferred into the host cell by virtue of the virus entering the cell and integrating its genome into the host cell genome.
  • retroviral vector refers to a viral particle capable of introducing exogenous nucleic acid into a cell through a viral or viral-like entry mechanism.
  • Retroviruses carry their genetic mformation in the form of RNA; however, once the virus infects a cell, the RNA is reverse-transcribed into the DNA form which integrates into the genomic DNA of the infected cell.
  • the integrated DNA form is called a provirus.
  • a vector construct refers to the polynucleotide comprising the viral genome or part thereof, and a transgene.
  • Ads adenoviruses
  • Ads are a relatively well characterized, homogenous group of viruses, including over 50 serotypes. See, e.g., WO 95/27071. Ads are easy to grow and do not require integration into the host cell genome. Recombinant Ad derived vectors, particularly those that reduce the potential for recombination and generation of wild- type virus, have also been constructed. See, WO 95/00655 and WO 95/11984. Wild- type AAV has high infectivity and specificity integrating into the host cell's genome.
  • Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression.
  • Gene delivery vehicles also include several non-viral vectors, including DNA/liposome complexes, recombinant yeast cells, and targeted viral protein-DNA complexes. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention.
  • the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens, e.g., TCR, CD3 or CD4.
  • a "probe” when used in the context of polynucleotide manipulation refers to an oligonucleotide that is provided as a reagent to detect a target potentially present in a sample of interest by hybridizing with the target.
  • a probe will comprise a label or a means by which a label can be attached, either before or subsequent to the hybridization reaction.
  • Suitable labels include, but are not limited to radioisotopes, fluorochromes, chemiluminescent compounds, dyes, and proteins, including enzymes.
  • a “primer” is a short polynucleotide, generally with a free 3 ' -OH group that binds to a target or "template” potentially present in a sample of interest by hybridizing with the target, and thereafter promoting polymerization of a polynucleotide complementary to the target.
  • a “polymerase chain reaction” (“PCR”) is a reaction in which replicate copies are made of a target polynucleotide using a "pair of primers” or a “set of primers” consisting of an "upstream” and a “downstream” primer, and a catalyst of polymerization, such as a DNA polymerase, and typically a thermally-stable polymerase enzyme.
  • PCR A PRACTICAL APPROACH
  • All processes of producing replicate copies of a polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "replication.”
  • a primer can also be used as a probe in hybridization reactions, such as Southern or Northern blot analyses. Sambrook et al, supra.
  • An expression “database” denotes a set of stored data that represent a collection of sequences, which in turn represent a collection of biological reference materials.
  • cDNAs refers to complementary DNA that are mRNA molecules present in a cell or organism made into cDNA with an enzyme such as reverse transcriptase.
  • a "cDNA library” is a collection of all of the mRNA molecules present in a cell or organism, all turned into cDNA molecules with the enzyme reverse transcriptase or an equivalent, then inserted into “vectors” (other DNA molecules that can continue to replicate after addition of foreign DNA).
  • vectors for libraries include bacteriophage (also known as "phage"), viruses that infect bacteria, for example, lambda phage. The library can then be probed for the specific cDNA
  • expression refers to the process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell. "Differentially expressed” as applied to a gene, refers to the differential production of the mRNA transcribed and/or translated from the gene or the protein product encoded by the gene. A differentially expressed gene may be overexpressed or underexpressed as compared to the expression level of a normal or control cell.
  • solid phase support or “solid support”, used interchangeably, is not limited to a specific type of support. Rather a large number of supports are available and are known to one of ordinary skill in the art. Solid phase supports include silica gels, resins, derivatized plastic films, glass beads, cotton, plastic beads, alumina gels, microarrays and chips.
  • solid support also includes synthetic antigen-presenting matrices, cells, and liposomes.
  • a suitable solid phase support may be selected on the basis of desired end use and suitability for various protocols.
  • solid phase support may refer to resins such as polystyrene (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), POLYHIPE® resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TentaGel®, Rapp Polymere, Tubingen, Germany) or polydimethylacrylamide resin (obtained from Milligen/Biosearch, California).
  • polystyrene e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.
  • POLYHIPE® resin obtained from Aminotech, Canada
  • polyamide resin obtained from Peninsula Laboratories
  • a polynucleotide also can be attached to a solid support for use in high throughput screening assays.
  • PCT WO 97/10365 discloses the construction of high density oligonucleotide chips. See also, U.S. Patent Nos. 5,405,783; 5,412,087; and 5,445,934.
  • the probes are synthesized on a derivatized glass surface also known as chip arrays.
  • Photoprotected nucleoside phosphoramidites are coupled to the glass surface, selectively deprotected by photolysis through a photolithographic mask, and reacted with a second protected nucleoside phosphoramidite. The coupling/deprotection process is repeated until the desired probe is complete.
  • Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues.
  • the hydrogen bonding may occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner.
  • the complex may comprise two strands forming a duplex structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these.
  • a hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.
  • Hybridization reactions can be performed under conditions of different "stringency".
  • a low stringency hybridization reaction is carried out at about 40 ⁇ C in 10 x SSC or a solution of equivalent ionic strength/temperature.
  • a moderate stringency hybridization is typically performed at about 50 °C in 6 x SSC, and a high stringency hybridization reaction is generally performed at about 60 °C in 1 x SSC.
  • annealing When hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides, the reaction is called “annealing" and those polynucleotides are described as “complementary”.
  • a double-stranded polynucleotide can be "complementary” or “homologous” to another polynucleotide, if hybridization can occur between one of the strands of the first polynucleotide and the second.
  • “Complementarity” or “homology” is quantifiable in terms of the proportion of bases in opposing strands that are expected to form hydrogen bonding with each other, according to generally accepted base-pairing rules.
  • a polynucleotide or polynucleotide region has a certain percentage (for example, 80%, 85%, 90%, or 95%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences.
  • This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F.M. Ausubel et al, eds., 1987) Supplement 30, section
  • default parameters are used for alignment.
  • a preferred alignment program is BLAST, using default parameters.
  • Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function.
  • Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell. Metaplasia can occur in epithelial or connective tissue cells. Atypical metaplasia involves a somewhat disorderly metaplastic epithelium. As used herein, the terms “neoplastic cells”, “neoplasia”, “tumor”, “tumor cells”, “cancer” and “cancer cells”, (used interchangeably) refer to cells which exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype characterized by a significant loss of control of cell proliferation (i.e., de-regulated cell division). Neoplastic cells can be malignant or benign. A metastatic cell or tissue means that the cell can invade and destroy neighboring body structures.
  • “Suppressing" tumor growth indicates a growth state that is curtailed when compared to growth without contact with educated, antigen-specific immune effector cells described herein.
  • Tumor cell growth can be assessed by any means known in the art, including, but not limited to, measuring tumor size, determining whether tumor cells are proliferating using a 3 H-thymidine incorporation assay, or counting tumor cells.
  • "Suppressing" tumor cell growth means any or all of the following states: slowing, delaying, and stopping tumor growth, as well as tumor shrinkage.
  • composition is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.
  • a “pharmaceutical composition” is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
  • the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin, REMINGTON' S PHARM. SCL, 15th Ed. (Mack Publ. Co., Easton (1975)).
  • an "effective amount” is an amount sufficient to effect beneficial or desired results such as prevention or treatment.
  • An effective amount can be admimstered in one or more administrations, applications or dosages.
  • a “subject,” “individual” or “patient” is used interchangeably herein, which refers to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.
  • a “control” is an alternative subject or sample used in an experiment for comparison purpose.
  • a control can be "positive” or “negative”.
  • the purpose of the experiment is to determine a correlation of an altered expression level of a gene with a particular type of cancer, it is generally preferable to use a positive control (a subject or a sample from a subject, carrying such alteration and exhibiting symptoms characteristic of that disease), and a negative control (a subject or a sample from a subject lacking the altered expression and clinical syndrome of that disease).
  • this invention provides various methods for aiding in the diagnosis of the neoplastic state of a lung cell that is characterized by abnormal cell growth in the form of, e.g. , malignancy, hyperplasia or metaplasia.
  • the methods are particularly useful for aiding in the diagnosis of non-small cell lung cancer cell.
  • the neoplastic state of a cell generally is determined by noting whether or not the growth of the cell is governed by the usual limitation of normal growth.
  • the term also is to include genotypic changes that occur prior to detection of this growth in the form of a tumor and are causative of these phenotypic changes.
  • the phenotypic changes associated with the neoplastic state of a cell include a more rounded cell morphology, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, release of proteases such as plasminogen activator, increased sugar transport, decreased serum requirement, expression of fetal antigens and the like. (See, Luria et al. (1978) GENERAL VIROLOGY, 3 d edition, 436-446 (John Wiley & Sons, New York)).
  • one embodiment is a method of diagnosing the condition of a lung cell by screening for the presence of a differentially expressed gene isolated from a sample containing or suspected of containing a lung cell, in which the differential expression of the gene is indicative of the neoplastic state of the lung cell.
  • the gene is expressed more in a neoplastic lung cell or a lung tumor cell as compared to normal lung cell, and is selected from EGFR-RS, RYK, TNFRSF25, TRPM7, KCP3, and KIAA 1883.
  • the gene is expressed more in a normal lung cell as compared to a neoplastic lung cell, e.g., UNC5H2.
  • Detection can be by any appropriate method, including for example, detecting the quantity of mRNA transcribed from the gene, or the quantity of cDNA produced from the reverse transcription of the mRNA transcribed from the gene, or the quantity of the polypeptide or protein encoded by the gene. Probes for each of these methods are provided in Table 1. These methods can be performed on a sample by sample basis or modified for high throughput analysis. Additionally, databases containing quantitative full or partial transcripts or protein sequences isolated from a cell sample can be searched and analyzed for the presence and amount of transcript or expressed gene product. In one aspect, the database contains at least one of the sequences shown in Table 1.
  • Epidermal Growth Factor Receptor-Related Sequence (referred to as "EGFR- RS" in Table 1) is a member of the epidermal growth factor receptor (EGFR) family which in turn is a member of a larger family of closely related transmembrane receptors (er ⁇ B receptors), all of which appear to be involved in the regulation of cellular growth, replication and/or differentiation.
  • ErbB includes four receptors, including EGFR (erbB-1), Her 2 (erbB-2), Her 3 (erbB-3) and Her 4 (erbB-4).
  • All four receptors share similar structure including an extracellular region which consists of glycosylated domains and binds to extracellular ligand, a short helical transmembrane domain secured by a single hydrophobic sequence and an intracellular tyrosine kinase domain that is responsible for initiating and regulating intracellular signaling.
  • One known exception to this is the erbB-3 receptor, which is activated tlirough other erbB tyrosine kinases, as erbB-3 lacks its own kinase activity.
  • the RYK gene encodes a protein comprised of two polypeptides, an approximately 80kD polypeptide and an approximately 45 kD polypeptide.
  • the gene is overexpressed in neuroblastomas, Wilms tumor, melanoma, ovarian cancer (epithelium and blood) and in leukemic cells.
  • Katso et al. (2000) Clin. Cancer Res. 6(8):3271-3281 has reported that overexpression of RYK is a prognostic indicator for ovarian cancer.
  • Overexpression of the gene has been reported to be transforming in vitro and in vivo.
  • RYK knockout mice have also been reported to be small and die within one week due to cleft palate.
  • EGFR has demonstrated high affinity to the ligands including, but not necessarily limited to: epidermal growth factor (EGF), transforming growth factor- alpha, amphiregulin, heparin-binding EGF, betacellulin and epiregulin.
  • Applicants have discovered overexpression of this gene in solid tumors of epithelium origin, e.g., lung carcinomas, breast carcinomas, metastatic breast carcinomas, primary ductal-breast carcinoma, mammary gland breast carcinoma and pleural effusion mammary gland carcinoma.
  • solid tumors of epithelium origin e.g., lung carcinomas, breast carcinomas, metastatic breast carcinomas, primary ductal-breast carcinoma, mammary gland breast carcinoma and pleural effusion mammary gland carcinoma.
  • Receptor-Like Tyrosine Kinase (referred to as "RYK” in Table 1) was reported by Hovens et al. (1992) PNAS 89: 11818- 11822, to be a novel member of the family of growth factor receptor protein tyrosine kinases. Comparison of mouse and human RYK cDNA sequences demonstrated a very high degree of sequence identity (Stacker et al. (1993) Oncogene 8:1347-1356). By genetic linkage analysis with recombinant inbred strains of mice, Gough et al. (1995) Mammalian Gen.
  • Tumor Necrosis Factor Receptor Superfamily, Member 25 (“TNFRSF25”) is also known as Death Receptor 3 ("DR3"), is a member of the mammalian tumor necrosis factor receptor (TNFR) family.
  • the TNFR family are cell-surface proteins that interact with a corresponding TNF-related ligand family.
  • the receptors share homology in the extracellular domain, which contains 3 to 6 cysteine-rich pseudorepeats, but are generally not related in their cytoplasmic regions.
  • the intracellular domains (ICDs) of TNFR family members e.g., TNFR1 and FAS/AP01/CD95, can activate apoptotic cell death. They have a region of homology in an oligomerization interface known as the death domain.
  • This gene was found to be overexpressed in breast carcinoma cells and induced rapid apoptosis in 293 cells.
  • the gene also induced NF-kB (unlike Fas) when 293 cells were cotransfected with DR3 and a NF-kB luciferase plasmid.
  • the gene is reported to be expressed in peripheral blood lymphocytes (PBLs) thymus, spleen, colon and small intestine. Kitson et al. (1996) Nature 384:372-375 previously reported that no expression has been reported in ovaries, testis, prostate, pancreas, kidney, skeletal muscle, liver lung, placenta, brain and heart.
  • TRPM7 is a mammalian homolog of the Drosophila transient receptor potential (tip) protein, which are known ion channels thought to mediate capacitative calcium entry into the cell. As a channel, these receptors conduct calcium and monovalent cations to depolarize cells and increase intracellular calcium. As a kinase, it is capable of phosphorylating itself and other substrates. The kinase activity is necessary for channel function, as shown by its dependence on intracellular ATP and by the kinase mutants.
  • tip Drosophila transient receptor potential
  • Unc5H2 Transmembrane Receptor Unc5H2 (referred to as "UNC5H2" in Table 1) was reported by Komatsuzaki K. et al. (2002) Biochem. Biophys. Res. Comm. 297(4):898-905, to be a G protein which are known to regulate a number of cellular functions including cell migration, proliferation, and differentiation. It is also reported that UNC5H2 is widely expressed particularly in cells which migrate.
  • KIAA1883 is one of 60 cDNA clones identified as an extension of a sequencing project to identify large proteins of unidentified genes. Nagase et al. (2001) DNA Res. 8:179-187. Nagase et al. reported that the cDNAs were isolated from libraries derived from human fetal brain, adult whole brain and amygdala.
  • gene expression is determined by noting the amount (if any, e.g., altered) expression of the gene in the test system at the level of an mRNA transcribed from at least one gene identified in Table 1.
  • augmentation of the level of the polypeptide or protein encoded by the gene is indicative of the presence of the neoplastic condition of the cell.
  • a decrease in the level of polypeptide or protein encoded by the gene is indicative of the neoplastic condition.
  • the method can be used for aiding in the diagnosis of lung cancer such as non-small cell lung cancer by detecting a genotype that is correlated with a phenotype characteristic of primary lung tumor cells. Thus, by detecting this genotype prior to tumor growth, one can predict a predisposition to cancer and/or provide early diagnosis and treatment.
  • Cell or tissue samples used for this invention encompass body fluid, solid tissue samples, tissue cultures or cells derived there from and the progeny thereof, and sections or smears prepared from any of these sources, or any other samples that may contain a lung cell having a gene described herein.
  • the sample comprises cells prepared from a subject's lung tissue.
  • nucleic acid contained in the aforementioned samples is first extracted according to standard methods in the art.
  • mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook et al. (1989) supra, or extracted by nucleic-acid-binding resins following the accompanying instructions provided by manufactures.
  • the mRNA of a proto-oncogene of interest contained in the extracted nucleic acid sample is then detected by hybridization (e.g., Northern blot analysis) and/or amplification procedures according to methods widely known in the art or based on the methods exemplified herein.
  • Nucleic acid molecules having at least 10 nucleotides and exhibiting sequence complementarity or homology to at least one gene identified in Table 1 find utility as hybridization probes. It is known in the art that a "perfectly matched" probe is not needed for a specific hybridization. Minor changes in probe sequence achieved by substitution, deletion or insertion of a small number of bases do not affect the hybridization specificity. In general, as much as 20% base-pair mismatch (when optimally aligned) can be tolerated.
  • a probe useful for detecting mRNA is at least about 80% identical to the homologous region of comparable size contained in the genes or polynucleotides identified in Table 1 identified sequences, which have the Locus Link numbers identified in Table 1.
  • the probe is 85% identical to the corresponding gene sequence after alignment of the homologous region, or alternatively, it exhibits 90% identity.
  • Additional probes can be derived from sequences for the genes identified by the Locus Link Nos. provided in Table 1, or to a homologous region of comparable size contained in the previously identified sequences, which have the Locus Link Nos. identified in Table 1. These probes can be used in radioassays (e.g., Southern and Northern blot analysis) to detect, prognose, diagnose or monitor various neoplastic states resulting from differential expression of a gene of interest.
  • the total size of fragment, as well as the size of the complementary stretches, will depend on the intended use or application of the particular nucleic acid segment. Smaller fragments derived from the known sequences will generally find use in hybridization embodiments, wherein the length of the complementary region may be varied, such as between about 10 and about 100 nucleotides, or even full length according to the complementary sequences one wishes to detect.
  • nucleotide probes having complementary sequences over stretches greater than about 10 nucleotides in length are used, so as to increase stability and selectivity of the hybrid, and thereby improving the specificity of particular hybrid molecules obtained.
  • Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCRTM technology with two priming oligonucleotides as described in U.S. Pat. No. 4,603,102 or by introducing selected sequences into recombinant vectors for recombinant production.
  • a probe is about 50 to about 75, nucleotides or alternatively, about 50 to about 100 nucleotides in length.
  • an appropriate means such as a label
  • a wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal.
  • fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmental undesirable reagents.
  • enzyme tags colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.
  • Hybridization reactions can be performed under conditions of different "stringency". Relevant conditions include temperature, ionic strength, time of incubation, the presence of additional solutes in the reaction mixture such as formamide, and the washing procedure. Higher stringency conditions are those conditions, such as higher temperature and lower sodium ion concentration, which require higher minimum complementarity between hybridizing elements for a stable hybridization complex to form. Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, for example, Sambrook et al. (1989) supra.
  • nucleotide probes of the present invention can also be used as primers and detection of genes or gene transcripts that are differentially expressed in certain body tissues. Additionally, a primer useful for detecting the aforementioned differentially expressed mRNA is at least about 80% identical to the homologous region of comparable size contained in the previously identified sequences, which have the
  • amplification means any method employing a primer-dependent polymerase capable of replicating a target sequence with reasonable fidelity.
  • Amplification may be carried out by natural or recombinant DNA-polymerases such as T7 DNA polymerase, Klenow fragment of E.coli DNA polymerase, and reverse transcriptase.
  • PCR MacPherson et al, PCR: A PRACTICAL APPROACH, (IRL Press at Oxford University Press (1991)).
  • PCR conditions used for each application reaction are empirically determined. A number of parameters influence the success of a reaction. Among them are annealing temperature and time, extension time, Mg 2+ ATP concentration, pH, and the relative concentration of primers, templates, and deoxyribonucleotides.
  • the resulting DNA fragments can be detected by agarose gel electrophoresis followed by visualization with ethidium bromide staining and ultraviolet illumination.
  • a specific amplification of differentially expressed genes of interest can be verified by demonstrating that the amplified DNA fragment has the predicted size, exhibits the predicated restriction digestion pattern, and/or hybridizes to the correct cloned DNA sequence.
  • the probes also can be attached to a solid support for use in high throughput screening assays using methods known in the art.
  • the probes of this invention are synthesized on a derivatized glass surface.
  • Photoprotected nucleoside phosphoramidites are coupled to the glass surface, selectively deprotected by photolysis through a photolithographic mask, and reacted with a second protected nucleoside phosphoramidite. The coupling/deprotection process is repeated until the desired probe is complete.
  • the expression level of a gene can also be determined through exposure of a nucleic acid sample to a probe-modified chip. Extracted nucleic acid is labeled, for example, with a fluorescent tag, preferably during an amplification step. Hybridization of the labeled sample is performed at an appropriate stringency level. The degree of probe-nucleic acid hybridization is quantitatively measured using a detection device, such as a confocal microscope. See U.S. Pat Nos. 5,578,832 and 5,631 ,734. The obtained measurement is directly correlated with gene expression level.
  • the probes and high density oligonucleotide probe arrays also provide an effective means of monitoring expression of the genes identified in Table 1. They are also useful to screen for compositions that upregulate or dow regulate the expression of the genes identified in Table 1.
  • the methods of this invention are used to monitor expression of the genes identified in Table 1 which specifically hybridize to the probes of this invention in response to defined stimuli, such as an exposure of a cell or subject to a drug.
  • the hybridized nucleic acids are detected by detecting one or more labels attached to the sample nucleic acids.
  • the labels may be incorporated by any of a number of means known to those of skill in the art. However, in one aspect, the label is simultaneously incorporated during the amplification step in the preparation of the sample nucleic acid.
  • PCR polymerase chain reaction
  • transcription amplification as described above, using a labeled nucleotide (e.g., fluorescein-labeled UTP and/or CTP) incorporates a label in to the transcribed nucleic acids.
  • a labeled nucleotide e.g., fluorescein-labeled UTP and/or CTP
  • a label may be added directly to the original nucleic acid sample (e.g. , mRNA, polyA, mRNA, cDNA, etc.) or to the amplification product after the amplification is completed.
  • Means of attaching labels to nucleic acids include, for example nick translation or end-labeling (e.g., with a labeled RNA) by kinasing of the nucleic acid and subsequent attachment (ligation) of a nucleic acid linker joining the sample nucleic acid to a label (e.g., a fluorophore).
  • Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
  • Useful labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., DynabeadsTM), fluorescent dyes (e.g., fluorescein, Texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g., 3 H, 125 1, 35 S, 14 C, or 32 P) enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
  • Patents teaching the use of such labels include U.S. Patents Nos. 3,817,837; 3,850,752; 3,939,350
  • radiolabels may be detected using photographic film or scintillation counters
  • fluorescent markers may be detected using a photodetector to detect emitted light
  • Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.
  • the label may be added to the target (sample) nucleic acid(s) prior to, or after the hybridization.
  • detectable labels that are directly attached to or incorporated into the target (sample) nucleic acid prior to hybridization.
  • indirect labels are joined to the hybrid duplex after hybridization.
  • the indirect label is attached to a binding moiety that has been attached to the target nucleic acid prior to the hybridization.
  • the target nucleic acid may be biotinylated before the hybridization. After hybridization, an avidin-conjugated fluorophore will bind the biotin bearing hybrid duplexes providing a label that is easily detected.
  • nucleic acid sample also may be modified prior to hybridization to the high density probe array in order to reduce sample complexity thereby decreasing background signal and improving sensitivity of the measurement using methods known in the art, e.g., the methods disclosed in WO 97/10365.
  • Results from the chip assay are typically analyzed using a computer software program. See, for example, EP 0717 113 A2 and WO 95/20681.
  • the hybridization data is read into the program, which calculates the expression level of the targeted gene(s) i.e., the genes identified in Table 1. This figure is compared against existing data sets of gene expression levels for diseased and healthy individuals. A correlation between the obtained data and that of a set of diseased individuals indicates the onset of a disease in the subject patient.
  • a data base useful for the detection of neoplastic lung tissue comprising one or more of the sequences (or parts thereof) of the genes listed Table 1.
  • These polynucleotide sequences are stored in a digital storage medium such that a data processing system for standardized representation of the genes that identify a lung cancer cell is compiled.
  • the data processing system is useful to analyze gene expression between two cells by first selecting a cell suspected of being of a neoplastic phenotype or genotype and then isolating polynucleotides from the cell.
  • the isolated polynucleotides are then sequenced.
  • the sequences from the sample are compared with the sequence(s) present in the database using homology search techniques described above.
  • greater than 90% is selected, or alternatively greater than 95% is selected, or alternatively greater than or equal to 97% sequence identity is selected, between the test sequence and at least one sequence identified in Table 1 or its complement, is a positive indication that the polynucleotide has been isolated from a lung cancer cell as defined above.
  • RNAs are isolated from cell or tissue samples using methods known in the art and described for example, in Sambrook et al. (1989) supra.
  • the gene transcripts can be converted to cDNA.
  • a sampling of the gene transcripts are subjected to sequence-specific analysis and quantified. These gene transcript sequence abundances are compared against reference database sequence abundances including normal data sets for diseased and healthy patients. The patient has the disease(s) with which the patient's data set most closely correlates which includes the overexpression of the transcripts identified herein.
  • Differential expression of the genes of interest can also be determined by examining the protein product.
  • a variety of techniques are available in the art for protein analysis. They include but are not limited to radioimmunoassays, ELISA
  • One means to determine protein level involves (a) providing a biological sample containing polypeptides; and (b) measuring the amount of any immunospecific binding that occurs between an antibody reactive to the expression product of a gene of interest and a component in the sample, in which the amount of immunospecific binding indicates the level of the expressed proteins. Antibodies that specifically recognize and bind to the protein products of these genes are required for these immunoassays.
  • a diagnostic test includes a control sample derived from a subject (hereinafter “positive control”), that exhibits the predicted change in expression of a gene of interest, e.g. , at a level of at least 2.5 fold and clinical characteristics of the malignancy or metaplasia of interest.
  • a diagnosis also includes a control sample derived from a subject (hereinafter “negative control”), that lacks the clinical characteristics of the neoplastic state and whose expression level of the gene at question is within a normal range.
  • a positive correlation between the subject and the positive control with respect to the identified alterations indicates the presence of or a predisposition to said disease.
  • a lack of correlation between the subject and the negative control confirms the diagnosis.
  • the method is used for diagnosing lung cancer, preferably non- small lung cancer, on the basis of a differential expression of a gene of Table 1
  • determination of the mRNA level of the aforementioned genes may involve, in one aspect, measuring the amount of mRNA in a sample isolated from the lung cell by hybridization or quantitative amplification using at least one oligonucleotide probe that is complementary to the mRNA. Determination of the aforementioned gene products requires measuring the amount of immunospecific binding that occurs between an antibody reactive to the gene product of a gene identified in Table 1. To detect and quantify the immunospecific binding, or signals generated during hybridization or amplification procedures, digital image analysis systems including but not limited to those that detect radioactivity of the probes or chemiluminescence can be employed.
  • the present invention also provides a screen for identifying leads, drugs, therapeutic biologies, and methods for reversing the neoplastic condition of the cells or selectively inhibiting growth or proliferation of the cells described above.
  • the screen identifies lead compounds or biological agents which are useful for the treatment of malignancy, hyperplasia or metaplasia characterized by differential expression of a gene identified in Table 1.
  • suitable cell cultures or tissue cultures are first provided.
  • the cell can be a cultured cell or a genetically modified cell which differentially expresses a gene associated with a neoplastic lung cell e.g., at least one gene identified in Table 1.
  • the cells can be from a tissue biopsy.
  • the cells are cultured under conditions (temperature, growth or culture medium and gas (C0 2 )) and for an appropriate amount of time to attain exponential proliferation without density dependent constraints. It also is desirable to maintain an additional separate cell culture; one which does not receive the agent being tested as a control.
  • the method can be modified for high throughput analysis and suitable cells may be cultured in microtiter plates and several agents may be assayed at the same time by noting genotypic changes, phenotypic changes and/or cell death.
  • the agent is a composition other than a DNA or RNA nucleic acid molecule
  • the suitable conditions comprise directly added to the cell culture or added to culture medium for addition.
  • an "effective" amount must be added which can be empirically determined.
  • the screen involves contacting the agent with a test cell characterized by differential expression of a gene of interest and then assaying the cell for the level of said gene expression. In some aspects, it may be necessary to determine the level of gene expression prior to the assay. This provides a base line to compare expression after administration of the agent to the cell culture.
  • the test cell is a cultured cell from an established cell line that differentially expresses a gene of interest.
  • An agent is a possible therapeutic agent if gene expression is returned (reduced or increased) to a level that is present in a cell in a normal or non-neoplastic state, or the cell selectively dies, or exhibits reduced rate of growth.
  • the test cell or tissue sample is isolated from the subject to be treated and one or more potential agents are screened to determine the optimal therapeutic and/or course of treatment for that individual patient.
  • an "agent” is intended to include, but not be limited to a biological or chemical compound such as a simple or complex organic or inorganic molecule, a peptide, a protein or an oligonucleotide.
  • a vast array of compounds can be synthesized, for example oligomers, such as oligopeptides and oligonucleotides, and synthetic organic compounds based on various core structures, and these are also included in the term "agent".
  • various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. It should be understood, although not always explicitly stated that the agent is used alone or in combination with another agent, having the same or different biological activity as the agents identified by the inventive screen. The agents and methods also are intended to be combined with other therapies.
  • the term "reversing the neoplastic state of the cell” is intended to include apoptosis, necrosis or any other means of preventing cell division, reduced tumorigenicity, loss of pharmaceutical resistance, maturation, differentiation or reversion of the neoplastic phenotypes as described herein.
  • lung cells having differential expression of a gene of interest that results in the neoplastic state are suitably treated by this method. These cells can be identified by any method known in the art that allows for the identification of differential expression of the gene.
  • the agent is a nucleic acid, it can be added to the cell cultures by methods known in the art, which includes, but is not limited to calcium phosphate precipitation, microinjection or electroporation.
  • the nucleic acid can be incorporated into an expression or insertion vector for incorporation into the cells.
  • Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art and briefly described infra.
  • Polynucleotides are inserted into vector genomes using methods well known in the art.
  • insert and vector DNA can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase.
  • synthetic nucleic acid linkers can be ligated to the termini of restricted polynucleotide. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA.
  • an oligonucleotide containing a termination codon and an appropriate restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; versatile multiple cloning sites; and T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA.
  • a selectable marker gene such as the neomycin gene for selection of stable or transient transfectants in mammalian cells
  • enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription
  • transcription termination and RNA processing signals from SV40 for mRNA stability transcription termination and RNA processing
  • Cellular differentiation can be monitored by histological methods or by monitoring for the presence or loss of certain cell surface markers, which may be associated with an undifferentiated phenotype, e.g., the expression products of at least one gene selected from EGFR-RS, RYK, TNFRSF25, and TRPM7.
  • Kits containing the agents and instructions necessary to perform the screen and in vitro method as described herein also are claimed.
  • a candidate agent is a potential drug if gene expression is returned to a normal level or if symptoms associated or correlated to the presence of cells containing differential expression of a gene of interest are ameliorated, each as compared to untreated, animal having the pathological cells. It also can be useful to have a separate negative control group of cells or animals which are healthy and not treated, which provides a basis for comparison.
  • Applicants have identified the death domain within the intracellular regions of the gene expression products identified in Table 1 as TNFRSF25, and UNC5H2.
  • ligands are known in the art and include, but are not limited to polyclonal and monoclonal antibodies as well as small molecules that bind to the extracellular portion of these receptors. Thus, these ligands are useful as therapeutic agents to inhibit growth of cells expressing these receptors.
  • any one of the gene expression products of the genes identified in Table 1 as EGFR-RS, RYK, TNFRSF25, TRPM7, UNC5H2 and KIAA1883 has sequence similarity to the receptor tyrosine kinase proteins.
  • Receptor tyrosine kinase proteins contain at least seven structural variants. All of the receptor tyrosine kinases are composed of at least three domains: an extracellular glycosylated ligand binding domain, a transmembrane domain and a cytoplasmic catalytic domain that can phosphorylate tyrosine residues. Ligand binding to membrane-bound receptors induces the formation of receptor dimers and allosteric changes that activate the intracellular kinase domains and result in the self- phosphorylation (autophosphorylation and/or transphosphorylation) of the receptor on tyrosine residues.
  • agents that inhibit receptor activation such as small molecules and antibodies that bind to the receptor's natural ligand are useful to inhibit proliferation of cells expressing these receptors.
  • Polynucleotides expressing these ligands and host cells containing them are also useful as therapeutic agents.
  • Therapeutic agents also include immune effector cells that specifically recognize and lyse cells expressing a gene identified in Table 1. One can determine if a subject or patient will be beneficially treated by the use of these immune effector cells by screening one or more of the effector cells against tumor cells isolated from the subject or patient using methods known in the art.
  • the therapeutic agent is administered in an amount effective to treat lung cancer.
  • an agent of the invention is administered in an amount effective to treat non-small cell lung cancer.
  • Therapeutics of the invention can also be used to prevent progression from a pre- neoplastic or non-malignant state into a neoplastic or a malignant state.
  • a therapeutic agent of the invention e.g. , encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis (See, e.g., Wu and Wu, (1987), J. Biol. Chem. 262:4429-4432), construction of a therapeutic nucleic acid as part of a retroviral or other vector, etc.
  • Methods of delivery include but are not limited to intra-arterial, intra-muscular, intravenous, intranasal, and oral routes.
  • the agents identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing a disease correlated to the differential expression of a gene of Table 1.
  • the agent When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject.
  • a tumor sample is removed from the patient and the cells are assayed for the differential expression of the gene.
  • Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent. When delivered to an animal, the method is useful to further confirm efficacy of the agent.
  • mice groups of nude mice (Balb/c NCR nu/nu female, Simonsen, Gilroy, CA) are each subcutaneously inoculated with about 10 5 to about 10 9 hyperproliferative, cancer or target cells as defined herein.
  • the agent is administered, for example, by subcutaneous injection around the tumor. Tumor measurements to determine reduction of tumor size are made in two dimensions using venier calipers twice a week. Other animal models may also be employed as appropriate.
  • Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment.
  • the agents and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.
  • the pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders.
  • the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention.
  • an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parental (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.
  • the agent should be administered to achieve peak concentrations of the active compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or orally administered, for example, as a tablet, capsule or syrup containing the active ingredient. Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue.
  • operative combinations is contemplated to provide therapeutic combinations requiring a lower total dosage of each component antiviral agent than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects.
  • compositions comprising at least one active ingredient, as defined above, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic agents.
  • Each carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol or oil.
  • a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active ingredients and optionally one or more excipients or diluents.
  • the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-l,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the agent through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While this phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at lease one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
  • the choice of suitable, oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate.
  • Formulations suitable for nasal administration wherem the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer include aqueous or oily solutions of the agent.
  • Formulations suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
  • the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of an agent.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies.
  • the genes of Table 1 can be used to generate transgenic animal models.
  • geneticists have succeeded in creating transgenic animals, for example mice, by manipulating the genes of developing embryos and introducing foreign genes into these embryos. Once these genes have integrated into the genome of the recipient embryo, the resulting embryos or adult animals can be analyzed to determine the function of the gene.
  • the mutant animals are produced to understand the function of known genes in vivo and to create animal models of human diseases. (See, e.g., Chisaka et al. (1992) 355:516-520; Joyner et al.
  • antibody capable of specifically forming a complex with the expression product of a gene of interest.
  • antibody includes polyclonal antibodies and monoclonal antibodies.
  • the antibodies include, but are not limited to mouse, rat, and rabbit or human antibodies.
  • the antibodies are useful to identify and purify gene expression products as well as APCs expressing the polypeptides.
  • the monoclonal antibodies of this invention can be biologically produced by introducing protein or a fragment thereof into an animal, e.g., a mouse or a rabbit.
  • the antibody producing cells in the animal are isolated and fused with myeloma cells or hetero- myeloma cells to produce hybrid cells or hybridomas. Accordingly, the hybridoma cells producing the monoclonal antibodies of this invention also are provided.
  • a monoclonal antibody being tested binds with tlie protein or polypeptide, then the antibody being tested and the antibodies provided by the hybridomas of this invention are equivalent. It also is possible to determine without undue experimentation, whether an antibody has the same specificity as the monoclonal antibody of this invention by determining whether the antibody being tested prevents a monoclonal antibody of this invention from binding the protein or polypeptide with which the monoclonal antibody is normally reactive. If the antibody being tested competes with the monoclonal antibody of the invention as shown by a decrease in binding by the monoclonal antibody of this invention, then it is likely that the two antibodies bind to the same or a closely related epitope.
  • the monoclonal antibody of this invention can pre- incubate the monoclonal antibody of this invention with a protein with which it is normally reactive, and determine if the monoclonal antibody being tested is inhibited in its ability to bind the antigen. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or a closely related, epitopic specificity as the monoclonal antibody of this invention.
  • antibody also is intended to include antibodies of all isotypes.
  • Particular isotypes of a monoclonal antibody can be prepared either directly by selecting from the initial fusion, or prepared secondarily, from a parental hybridoma secreting a monoclonal antibody of different isotype by using the sib selection technique to isolate class switch variants using the procedure described in Steplewski et al. (1985) Proc. Natl. Acad. Sci. USA 82:8653 or Spira et al. (1984) J. Immunol. Meth. 74:307.
  • antibody fragments retain some ability to selectively bind with its antigen or immunogen.
  • antibody fragments can include, but are not limited to:
  • a specific example of "a biologically active antibody fragment” is a CDR region of the antibody. Methods of making these fragments are known in the art, see for example, Harlow and Lane (1988) supra.
  • the antibodies of this invention also can be modified to create chimeric antibodies and humanized antibodies (Oi et al. (1986) BioTechniques 4(3):214). Chimeric antibodies are those in which the various domains of the antibodies' heavy and light chains are coded for by DNA from more than one species.
  • the isolation of other hybridomas secreting monoclonal antibodies with the specificity of the monoclonal antibodies of the invention can also be accomplished by one of ordinary skill in the art by producing anti-idiotypic antibodies (Herlyn et al. (1986) Science 232:100).
  • An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the monoclonal antibody produced by the hybridoma of interest. Idiotypic identity between monoclonal antibodies of two hybridomas demonstrates that the two monoclonal antibodies are the same with respect to their recognition of the same epitopic determinant. Thus, by using antibodies to the epitopic determinants on a monoclonal antibody it is possible to identify other hybridomas expressing monoclonal antibodies of the same epitopic specificity.
  • an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the mirror image of the epitope bound by the first monoclonal antibody.
  • the anti-idiotypic monoclonal antibody could be used for immunization for production of these antibodies.
  • epitopic determinants are meant to include any determinant having specific affinity for the monoclonal antibodies of the invention.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • the antibodies of this invention can be linked to a detectable agent or label.
  • labels and methods of labeling known to those of ordinary skill in the art.
  • the coupling of antibodies to low molecular weight haptens can increase the sensitivity of the assay.
  • the haptens can then be specifically detected by means of a second reaction.
  • haptens such as biotin, which reacts avidin, or dinitrophenol, pyridoxal, and fluorescein, which can react with specific anti-hapten antibodies. See, Harlow and Lane (1988) supra.
  • the monoclonal antibodies of the invention also can be bound to many different carriers.
  • this invention also provides compositions containing the antibodies and another substance, active or inert.
  • Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite.
  • the nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such, using routine experimentation.
  • compositions containing the antibodies, fragments thereof or cell lines which produce the antibodies are encompassed by this invention.
  • compositions are to be used pharmaceutically, they are combined with a pharmaceutically acceptable carrier.
  • the present invention provides a method of inducing an immune response comprising delivering the compounds and compositions of the invention in the context of an MHC molecule.
  • the polypeptides of this invention can be pulsed into antigen presenting cells using the methods described herein.
  • Antigen-presenting cells include, but are not limited to dendritic cells (DCs), monocytes/macrophages, B lymphocytes or other cell type(s) expressing the necessary MHC/co-stimulatory molecules.
  • DCs dendritic cells
  • monocytes/macrophages include, but are not limited to dendritic cells (DCs), monocytes/macrophages, B lymphocytes or other cell type(s) expressing the necessary MHC/co-stimulatory molecules.
  • DCs dendritic cells
  • monocytes/macrophages include, but are not limited to monocytes/macrophages, B lymphocytes or other cell type(s) expressing the necessary MHC/co-stimulatory molecules.
  • Isolated host cells which present the polypeptides of this invention in the context of MHC molecules are further useful to expand and isolate a population of educated, antigen-specific immune effector cells.
  • the immune effector cells e.g., cytotoxic T lymphocytes
  • the population can be purified using methods known in the art, e.g., FACS analysis or ficoll gradient.
  • the methods to generate and culture the immune effector cells as well as the populations produced thereby also are the inventor's contribution and invention.
  • Pharmaceutical compositions comprising the cells and pharmaceutically acceptable carriers are useful in adoptive immunotherapy. Prior to administration in vivo, the immune effector cells are screened in vitro for their ability to lyse tumor cells
  • the immune effector cells and/or the APCs are genetically modified.
  • genes coding for co-stimulatory molecules and/or stimulatory cytokines can be inserted prior to, concurrent to or subsequent to expansion of the immune effector cells.
  • This invention also provides methods of inducing an immune response in a subject, comprising administering to the subject an effective amount of a polypeptide described above under the conditions that induce an immune response to the polypeptide.
  • the polypeptide can be administered in a formulation or as a polynucleotide encoding the polypeptide.
  • the polynucleotide can be administered in a gene delivery vehicle or by inserting into a host cell which in turn recombinantly transcribes, translates and processed the encoded polypeptide.
  • Isolated host cells containing the polynucleotides of this invention in a pharmaceutically acceptable carrier can therefore be combined with appropriate and effective amount of an adjuvant, cytokine or co-stimulatory molecule for an effective vaccine regimen.
  • the host cell is an APC such as a dendritic cell.
  • the host cell can be further modified by inserting of a polynucleotide coding for an effective amount of either or both a cytokine and/or a co-stimulatory molecule.
  • the methods of this invention can be further modified by co-administering an effective amount of a cytokine or co-stimulatory molecule to the subject.
  • compositions containing any of the above- mentioned proteins, polypeptides, polynucleotides, vectors, cells, antibodies and fragments thereof, and an acceptable solid or liquid carrier.
  • compositions are used pharmaceutically, they are combined with a "pharmaceutically acceptable carrier" for diagnostic and therapeutic use.
  • CCE countercurrent centrifugal elutriation
  • cells are subject to simultaneous centrifugation and a washout stream of buffer that is constantly increasing in flow rate.
  • the constantly increasing countercurrent flow of buffer leads to fractional cell separations that are largely based on cell size.
  • the APC are precommitted or mature dendritic cells which can be isolated from the white blood cell fraction of a mammal, such as a murine, simian or a human (See, e.g., WO 96/23060).
  • the white blood cell fraction can be from the peripheral blood of the mammal.
  • This method includes the following steps: (a) providing a white blood cell fraction obtained from a mammalian source by methods known in the art such as leukapheresis; (b) separating the white blood cell fraction of step (a) into four or more subtractions by countercurrent centrifugal elutriation; (c) stimulating conversion of monocytes in one or more fractions from step (b) to dendritic cells by contacting the cells with calcium ionophore, GM-CSF and IL-13 or GM-CSF and IL-4, (d) identifying the dendritic cell-enriched fraction from step (c); and (e) collecting the enriched fraction of step (d), is performed at about 4°C.
  • the white blood cell fraction can be treated with calcium ionophore in the presence of other cytokines, such as recombinant (rh) rhIL-12, rhGM-CSF, or rhIL-4.
  • the cells of the white blood cell fraction can be washed in buffer and suspended in Ca ⁇ /Mg free media prior to the separating step.
  • the white blood cell fraction can be obtained by leukapheresis.
  • the dendritic cells can be identified by the presence of at least one of the following markers: HLA-DR, HLA- DQ, or B7. 2, and the simultaneous absence of the following markers: CD3, CD14, CD16, 56, 57, and CD 19, 20. Monoclonal antibodies specific to these cell surface markers are commercially available.
  • the method requires collecting an enriched collection of white cells and platelets from leukapheresis that is then further fractionated by countercurrent centrifugal elutriation (CCE) (Abrahamsen T.G. et al. (1991) J. Clin. Apheresis. 6:48-53).
  • CCE countercurrent centrifugal elutriation
  • Cell samples are placed in a special elutriation rotor.
  • the rotor is then spun at a constant speed of, for example, 3000 rpm. Once the rotor has reached the desired speed, pressurized air is used to control the flow rate of cells.
  • Cells in the elutriator are subjected to simultaneous centrifugation and a washout stream of buffer that is constantly increasing in flow rate. This results in fractional cell separations based largely but not exclusively on differences in cell size.
  • DCs Quality control of APC and more specifically DC collection and confirmation of their successful activation in culture is dependent upon a simultaneous multi-color FACS analysis technique which monitors both monocytes and the dendritic cell subpopulation as well as possible contaminant T lymphocytes. It is based upon the fact that DCs do not express the following markers: CD3 (T cell); CD14 (monocyte); CD16, 56, 57 (NK/LAK cells); CD19, 20 (B cells). At the same time, DCs do express large quantities of HLA-DR, significant HLA-DQ and B7.2 (but little or no B7.1) at the time they are circulating in the blood (in addition they express Leu M7 and M9, myeloid markers which are also expressed by monocytes and neutrophils).
  • Color #1 CD3 alone, CD14 alone, etc.; Leu M7 or Leu M9; anti-Class I, etc.
  • This method involves the addition of calcium ionophore to the culture media to convert monocytes into activated dendritic cells.
  • Adding the calcium ionophore A23187, for example, at the beginning of a 24 to 48 hour culture period resulted in uniform activation and dendritic cell phenotypic conversion of the pooled "monocyte plus DC" fractions: characteristically, the activated population becomes uniformly
  • CD14 (Leu M3) negative, and upregulates HLA-DR, HLA-DQ, ICAM-1, B7.1, and B7.2. Furthermore, this activated bulk population functions as well on a small numbers basis and is easily purified.
  • cytokines include but are not limited to purified or recombinant ("rh") rhGM-CSF, rhIL-2, and rhIL-4. Each cytokine when given alone is inadequate for optimal upregulation.
  • Antigen-presenting cells can consist of dendritic cells (DCs), monocytes/macrophages, B lymphocytes or other cell type(s) expressing the necessary MHC/co-stimulatory molecules.
  • DCs dendritic cells
  • monocytes/macrophages monocytes/macrophages
  • B lymphocytes or other cell type(s) expressing the necessary MHC/co-stimulatory molecules.
  • Pulsing is accomplished in vitro/ex vivo by exposing APCs to the antigenic protein or peptide(s) of this invention.
  • the protein or peptide(s) is added to APCs at a concentration of 1-10 ⁇ m for approximately 3 hours.
  • Pulsed APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
  • Protein/peptide antigen can also be delivered in vivo with adjuvant via the intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
  • Paglia et al. (1996) J. Exp. Med. 183:317-322, has shown that APC incubated with whole protein in vitro were recognized by MHC class I-restricted CTLs, and that immunization of animals with these APCs led to the development of antigen-specific CTLs in vivo.
  • several different techniques have been described which lead to the expression of antigen in the cytosol of APCs, such as DCs. These include
  • Foster APCs are derived from the human cell line 174xCEM.T2, referred to as T2, which contains a mutation in its antigen processing pathway that restricts the association of endogenous peptides with cell surface MHC class I molecules (Zweerink et al. (1993) J. Immunol. 150: 1763-1771). This is due to a large homozygous deletion in the MHC class II region encompassing the genes TAP1, TAP2, LMP1, and LMP2, which are required for antigen presentation to MHC class 1 -restricted CD8 CTLs. In effect, only "empty" MHC class I molecules are presented on the surface of these cells.
  • T2 cells Exogenous peptide added to the culture medium binds to these MHC molecules provided that the peptide contains the allele- specific binding motif.
  • These T2 cells are referred to herein as "foster" APCs. They can be used in conjunction with this invention to present antigen(s).
  • T2 cells with specific recombmant MHC alleles allows for redirection of the MHC restriction profile.
  • Libraries tailored to the recombinant allele will be preferentially presented by them because the anchor residues will prevent efficient binding to the endogenous allele.
  • the immunogenicity of therapeutic agents of this invention can be determined by known methodologies including, but not limited to those exemplified below- In one embodiment, such methodology may be employed to compare an equivalent polypeptide ligand of the invention with the corresponding native ligand. For example, an altered ligand may be considered "more active" if it compares favorably with the activity of the native ligand in any one of the following assays. For some purposes, one skilled in the art will select an immunogenic ligand which displays more activity than another immunogenic ligand, i.e., for treatment and/or diagnostic purposes. However, for some applications, the use of an immunogenic ligand which is comparable with the native ligand will be suitable. In other situations, it may be desirable to utilize an immunogenic ligand which is less active. It has been suggested that such levels of activity positively correlate with the level of immunogenicity.
  • Cytokines can be measured by ELISA or ELISPOT assays to determine the rate and total amount of cytokine production. (Fujihashi K. et al. (1993) J. Immunol. Meth. 160:181; Tanguay S. and Killion J.J. (1994) Lymphokine Cytokine Res. 13:259).
  • the ligands of the invention can be compared to the corresponding native ligand for the ability to elicit ligand-reactive T cell populations from normal donor or patient-derived PBMC.
  • elicited T cells can be tested for lytic activity, cytokine-release, polyclonality, and cross- reactivity to the native ligand. (Parkhurst M.R. et al. (1996) J. Immunol. 157:2539).
  • Transgenic animal models Immunogenicity can be assessed in vivo by vaccinating HLA transgenic mice with either the ligands of the invention or the native ligand and determining the nature and magnitude of the induced immune response.
  • the hu-PBL-SCID mouse model allows reconstitution of a human immune system m a mouse by adoptive transfer of human PBL. These animals may be vaccinated with the ligands and analyzed for immune response as previously mentioned. (Shirai M. et al. (1995) J. Immunol. 154:2733; Mosier D.E. et al. (1993) Proc. Natl. Acad. Sci. USA 90:2443). 5. Proliferation. T cells will proliferate in response to reactive ligands.
  • Proliferation can be monitored quantitatively by measuring, for example, 3 H- thymidine uptake. (Caruso A. et al. (1997) Cytomefry 27:71).
  • MHC tetramers can be loaded with individual ligands and tested for their relative abilities to bind to appropriate effector T cell populations. (Airman J.D. et al. (1996) Science 274(5284):94-96).
  • MHC Stabilization Exposure of certain cell lines such as T2 cells to HLA-binding ligands results in the stabilization of MHC complexes on the cell surface. Quantitation of MHC complexes on the cell surface has been correlated with the affinity of the ligand for the HLA allele that is stabilized. Thus, this technique can determine the relative HLA affinity of ligand epitopes. (Stuber G. et al. (1995) Int.
  • MHC competition The ability of a ligand to interfere with the functional activity of a reference ligand and its cognate T cell effectors is a measure of how well a ligand can compete for MHC binding. Measuring the relative levels of inhibition is an indicator of MHC affinity. (Feltkamp M.C. et al. (1995) Immunol. Lett. 47: 1).
  • the present invention makes use of these APCs to stimulate production of an enriched population of antigen-specific immune effector cells.
  • the antigen-specific immune effector cells are expanded at the expense of the APCs, which die in the culture.
  • the process by which na ⁇ ve immune effector cells become educated by other cells is described essentially in Coulie (1997) Molec. Med. Today 3:261-268.
  • the APCs prepared as described above are mixed with na ⁇ ve immune effector cells.
  • the cells may be cultured in the presence of a cytokine, for example IL-2. Because dendritic cells secrete potent immunostimulatory cytokines, such as IL-12, it may not be necessary to add supplemental cytokines during the first and successive rounds of expansion. In any event, the culture conditions are such that the antigen- specific immune effector cells expand (i.e., proliferate) at a much higher rate than the APCs. Multiple infusions of APCs and optional cytokines can be performed to further expand the population of antigen-specific cells.
  • the immune effector cells are T cells.
  • the immune effector cells can be genetically modified by transduction with a transgene coding for example, IL-2, IL-11 or IL-13.
  • a transgene coding for example, IL-2, IL-11 or IL-13.
  • the most common viral vectors include recombinant poxviruses such as vaccinia and fowlpox virus (Bronte et al. (1997) Proc. Natl. Acad. Sci. USA 94:3183-3188; Kim et al. (1997) J. Immunother. 20:276-286) and as an example adenovirus (Arthur et al. (1997) J. Immunol. 159:1393-1403; Wan etal. (1997) Human Gene Therapy 8:1355- 1363; Huang et al. (1995) J. Virol. 69:2257-2263). Retrovirus also may be used for transduction of human APCs (Marin et al. (1996) J. Virol. 70:2957-2962).
  • Transduced APCs can subsequently be admimstered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
  • In vivo transduction of DCs, or other APCs can be accomplished by administration of Ad (or other viral vectors) via different routes including intravenous, intramuscular, intranasal, intraperitoneal or cutaneous delivery.
  • the method is cutaneous delivery of Ad vector at multiple sites using a total dose of approximately lxl0 10 -lx 10 12 i.u.
  • Levels of in vivo transduction can be roughly assessed by co-staining with antibodies directed against APC marker(s) and the TAA being expressed.
  • the staining procedure can be carried out on biopsy samples from the site of administration or on cells from draining lymph nodes or other organs where APCs (in particular DCs) may have migrated (Condon et al. (1996) Nature Med. 2:1122-1128 and Wan et /. (1997) Hum. Gene Ther. 8:1355-1363).
  • the amount of antigen being expressed at the site of injection or in other organs where transduced APCs may have migrated can be evaluated by ELISA on tissue homogenates.
  • DCs can also be transduced in vitro/ex vivo by non-viral gene delivery methods such as electroporation, calcium phosphate precipitation or cationic lipid/plasmid DNA complexes (Arthur et al. (1997) Cancer Gene Ther. 4:17-25).
  • Transduced APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
  • In vivo transduction of DCs, or other APCs can potentially be accomplished by administration of cationic lipid/plasmid DNA complexes delivered via the intravenous, intramuscular, intranasal, intraperitoneal or cutaneous route of administration.
  • transduction efficiency and levels of transgene expression can be assessed as described above for viral vectors.
  • the expanded populations of antigen-specific immune effector cells of the present invention also find use in adoptive immunotherapy regimes and as vaccines.
  • Adoptive immunotherapy methods involve, in one aspect, administering to a subject a substantially pure population of educated, antigen-specific immune effector cells made by culturing na ⁇ ve immune effector cells with APCs as described above.
  • the APCs are dendritic cells.
  • the adoptive immunotherapy methods described herein are autologous.
  • the APCs are made using parental cells isolated from a single subject.
  • the expanded population also employs T cells isolated from that subject.
  • the expanded population of antigen-specific cells is administered to the same patient.
  • an effective amount, APCs or immune effector cells are administered with an effective amount of a stimulatory cytokine, such as IL-2 or a co-stimulatory molecule.
  • a stimulatory cytokine such as IL-2 or a co-stimulatory molecule.
  • agents identified herein as effective for their intended purpose can be administered to subjects in need of such therapy.
  • Method for administration of therapeutic agents are known in the art and described briefly, supra.

Abstract

La présente invention se rapporte à des compositions et à des méthodes permettant d'aider au diagnostic de l'état néoplasique d'une cellule pulmonaire, ainsi qu'à des méthodes de criblage d'agents thérapeutiques potentiels permettant de neutraliser ledit état néoplasique. L'invention concerne également des compositions thérapeutiques et des méthodes permettant d'inhiber la croissance de cellules pulmonaires néoplasiques, et de traiter des sujets présentant des cellules pulmonaires néoplasiques.
PCT/US2004/011193 2003-04-10 2004-04-12 Compositions et methodes de diagnostic et de traitement du cancer du poumon WO2004091511A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/247,437 US20060110753A1 (en) 2004-04-12 2005-10-11 Methods to diagnose and treat lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46202803P 2003-04-10 2003-04-10
US60/462,028 2003-04-10

Publications (2)

Publication Number Publication Date
WO2004091511A2 true WO2004091511A2 (fr) 2004-10-28
WO2004091511A3 WO2004091511A3 (fr) 2004-11-25

Family

ID=33299893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011193 WO2004091511A2 (fr) 2003-04-10 2004-04-12 Compositions et methodes de diagnostic et de traitement du cancer du poumon

Country Status (1)

Country Link
WO (1) WO2004091511A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048264A2 (fr) * 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
WO2010067308A2 (fr) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides et polynucléotides, et utilisations de ceux-ci en tant que médicament cible pour produire des médicaments et des agents biologiques
WO2011124884A3 (fr) * 2010-04-07 2011-12-01 Imperial Innovations Limited Procédés
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US10570454B2 (en) 2007-09-19 2020-02-25 Trustees Of Boston University Methods of identifying individuals at increased risk of lung cancer
US10731223B2 (en) 2009-12-09 2020-08-04 Veracyte, Inc. Algorithms for disease diagnostics
WO2020201362A3 (fr) * 2019-04-02 2020-11-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOMATSUZAKI ET AL: 'Modulation of Gialpha2 signaling by the axonal guidance molecule UNC5H2' BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 297, October 2002, pages 898 - 905, XP002230577 *
NAGASE ET AL: 'Prediction of the coding sequences of unidentified human genes XXI. The complete sequences of 60 new cDNA clones from brain which code for large proteins' DNA RESEARCH vol. 8, 2001, pages 179 - 187, XP001055485 *
THIEBAULT ET AL: 'The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment' PNAS vol. 100, no. 7, 01 April 2003, pages 4173 - 4178, XP002982191 *
WANG ET AL: 'H-RYK, an unusual receptor kinase: Isolation and analysis of expression in ovarian cancer' MOLECULAR MEDICINE vol. 2, no. 2, March 1996, pages 189 - 203, XP002955750 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048264A3 (fr) * 2004-11-04 2006-09-21 Roche Diagnostics Gmbh Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
WO2006048264A2 (fr) * 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US10808285B2 (en) 2005-04-14 2020-10-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US10570454B2 (en) 2007-09-19 2020-02-25 Trustees Of Boston University Methods of identifying individuals at increased risk of lung cancer
WO2010067308A2 (fr) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides et polynucléotides, et utilisations de ceux-ci en tant que médicament cible pour produire des médicaments et des agents biologiques
EP2865689A1 (fr) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F polypeptides et polynucléotides, et leurs utilisations en tant que médicament cible pour produire des médicaments et des agents biologiques
US10731223B2 (en) 2009-12-09 2020-08-04 Veracyte, Inc. Algorithms for disease diagnostics
WO2011124884A3 (fr) * 2010-04-07 2011-12-01 Imperial Innovations Limited Procédés
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2020201362A3 (fr) * 2019-04-02 2020-11-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes

Also Published As

Publication number Publication date
WO2004091511A3 (fr) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2005055808A2 (fr) Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
US20020018766A1 (en) Genes differentially expressed in cancer cells to design cancer vaccines
WO1999065928A2 (fr) Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
US20060134682A1 (en) Preparation and use of superior vaccines
US20070065889A1 (en) Compositions and methods to diagnose and treat lung cancer
WO2004091511A2 (fr) Compositions et methodes de diagnostic et de traitement du cancer du poumon
JP2002541805A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
US8067240B2 (en) Methods for the diagnosis and treatment of lung cancer
US20030147866A1 (en) Novel BGP compounds for therapy and diagnosis and methods for using same
EP1086215A2 (fr) Preparation et utilisation de vaccins superieurs
US20060110753A1 (en) Methods to diagnose and treat lung cancer
US6861506B1 (en) Compositions and methods for the treatment and diagnosis of breast cancer
US20020122791A1 (en) Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
WO2005000099A2 (fr) Domaines de facteurs sanguins (bfd)
US20060111297A1 (en) Blood factor domains
WO2005006961A2 (fr) Peptides d'antigenes dd96
US20020197243A1 (en) Novel p53BP2 compounds for therapy and diagnosis and methods for using same
US20050196860A1 (en) Novel EPS8 compounds for therapy and diagnosis and methods for using same
US20020082216A1 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
US20050059056A1 (en) Antigenic gp100 (154-162) compounds for therapy and diagnosis and methods for using same
AU2003286850A8 (en) Antigenic gp 100 compounds for therapy and diagnosis and methods for using same
US20030013075A1 (en) MART-1 compounds for therapy and diagnosis and methods for using same
WO1999066303A2 (fr) Identification et utilisation de genes a expression differentielle et de sequences polynucleotidiques
US20020155471A1 (en) Compounds for therapy and diagnosis and methods for using same
WO2003064693A1 (fr) Composes mart-1 utiles en therapie et diagnostic et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11247437

Country of ref document: US

122 Ep: pct application non-entry in european phase